Education
About Us
Working with TipRanks
Follow Us
Eli Lilly And Company (LLY)
:LLY
LLY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$711.40 - $972.53
Previous CloseN/A
Volume1.27M
Average Volume (3M)3.58M
Market Cap
$794.01B
Enterprise Value$761.80B
Total Cash (Recent Filing)$2.46B
Total Debt (Recent Filing)$16.51B
Price to Earnings (P/E)71.5
Beta0.67
Next Earnings
May 01, 2025EPS Estimate
4.69Last Dividend Ex-Date
Feb 14, 2025Dividend Yield0.64%
Share Statistics
EPS (TTM)11.49
Shares Outstanding947,989,140
10 Day Avg. Volume3,847,713
30 Day Avg. Volume3,580,304
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)N/A
Price to Sales (P/S)17.63
Price to Cash Flow (P/CF)80.30
P/FCF Ratio203.10
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.80
Enterprise Value/Ebitda48.75
Forecast
1Y Price Target
$1,032.23Price Target Upside23.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Market PresenceLilly’s tirzepatide continues to increase its share of new written prescription starts among primary care physicians, highlighting its growing market presence.
Product PerformanceLilly’s Mounjaro has continued to see strong year-to-date gains among endocrinologists, indicating robust performance in this segment.
Regulatory SupportThe FDA's concerns with compounded GLP-1s, particularly Lilly’s tirzepatide, are expected to positively influence LLY stock.
Bears Say
CompetitionCagriSema weight loss data appear comparable cross-trial to LLY’s Zepbound, which showed up to roughly 15.5% absolute weight loss in T2D patients.
Manufacturing ChallengesCagriSema is more difficult to manufacture than tirzepatide due to its dual-chamber device, and NVO’s future manufacturing capacity is TBD.
Tolerability ConcernsDiscontinuation due to GI events was higher on CagriSema compared to sema, raising concerns about its tolerability.
---
Ownership Overview
10.30% Insiders
22.41% Mutual Funds
27.73% Other Institutional Investors
22.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LLY FAQ
What was Eli Lilly And Company’s price range in the past 12 months?
Eli Lilly And Company lowest stock price was $711.40 and its highest was $972.53 in the past 12 months.
What is Eli Lilly And Company’s market cap?
Eli Lilly And Company’s market cap is $794.01B.
When is Eli Lilly And Company’s upcoming earnings report date?
Eli Lilly And Company’s upcoming earnings report date is May 01, 2025 which is in 39 days.
How were Eli Lilly And Company’s earnings last quarter?
Eli Lilly And Company released its earnings results on Feb 06, 2025. The company reported $5.32 earnings per share for the quarter, beating the consensus estimate of $5.045 by $0.275.
Is Eli Lilly And Company overvalued?
According to Wall Street analysts Eli Lilly And Company’s price is currently Undervalued.
Does Eli Lilly And Company pay dividends?
Eli Lilly And Company pays a Quarterly dividend of $1.5 which represents an annual dividend yield of 0.64%. See more information on Eli Lilly And Company dividends here
What is Eli Lilly And Company’s EPS estimate?
Eli Lilly And Company’s EPS estimate is 4.69.
How many shares outstanding does Eli Lilly And Company have?
Eli Lilly And Company has 947,989,140 shares outstanding.
What happened to Eli Lilly And Company’s price movement after its last earnings report?
Eli Lilly And Company reported an EPS of $5.32 in its last earnings report, beating expectations of $5.045. Following the earnings report the stock price went up 3.347%.
Which hedge fund is a major shareholder of Eli Lilly And Company?
Currently, no hedge funds are holding shares in LLY
---
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,032.23 (23.24% Upside)
$1,032.23 (23.24% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 644.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.44%
12-Months-Change
Fundamentals
Return on Equity
84.84%
Trailing 12-Months
Asset Growth
22.98%
Trailing 12-Months
Company Description
Eli Lilly And Company
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and successful product launches, underpinned by strategic investments and advancements in the pipeline. However, challenges such as pricing pressures, a decline in Trulicity revenue, and supply constraints in certain regions tempered the overall positive outlook.Read More>---
LLY Revenue Breakdown
67.44% U.S.
15.36% Europe
9.48% ROW
4.03% Japan
3.69% China
---
LLY Stock 12 Month Forecast
Average Price Target
$1,032.23
▲(23.24% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
40/43 ratings generated profit
1 Year Average Return
+36.02%
reiterated a buy rating 14 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 93.02% of your transactions generating a profit, with an average return of +36.02% per trade.
---